Table 2.

Comparison of the change in BMI and lung function the year before and after 1 year of study participation

	CFRD FH−			IGT
	Insulin	Repaglinide	Placebo	Insulin	Repaglinide	Placebo
n		61			20
BMI
−12 months to baseline (kg/m2)	−0.30 ± 0.21	−0.14 ± 0.21	−0.29 ± 0.25	−0.60 ± 0.30	−0.08 ± 0.40	−0.66 ± 0.27
Baseline to +12 months (kg/m2)	0.39 ± 0.21	0.15 ± 0.21	−0.02 ± 0.25	−0.26 ± 0.30	−0.71 ± 0.40	0.24 ± 0.27
P value	0.02	0.33	0.45	0.43	0.28	0.02
FVC
−12 months to baseline (% predicted)	−5.8 ± 2.0	−5.5 ± 2.1	−4.3 ± 2.5	2.0 ± 4.2	−3.4 ± 5.6	−2.8 ± 3.7
Baseline to +12 months	−0.5 ± 2.0	−2.1 ± 2.1	−1.1 ± 2.5	−10.3 ± 4.2	−3.1 ± 5.6	−5.1 ± 3.7
P value	0.21	0.25	0.37	0.05	0.96	0.6
FEV1
−12 months to baseline (% predicted)	−5.7 ± 2.2	−6.5 ± 2.2	−0.5 ± 2.7	0.6 ± 5.6	−2.5 ± 7.4	2.8 ± 4.9
Baseline to +12 months	−1.8 ± 2.2	−1.3 ± 2.2	−3.0 ± 2.7	12.1 ± 5.6	−4.9 ± 7.4	−11.5 ± 4.9
P value	0.21	0.10	0.51	0.12	0.82	0.05

Data are means ± SEM.